Real-World Observational Study Using US Pharmacy Claims Data to Assess Safety Outcomes and Treatment Patterns in the US Among Migraine Patients Treated with REYVOW (Lasmiditan) Long Term (H8H-MC-B010)

17/04/2023
03/10/2025
EU PAS number:
EUPAS104191
Study
Planned
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

LY573144 H8H-MC-B010 Non_interventional PASS Protocol_Redacted

English (350.47 KB - PDF) View document
Study results
Study report
Other information